Avexa Limited
www.avexa.com.au
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avexa Limited
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future
Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability.
FDA Idea To ‘Encourage Competition For New Drugs’ Spares Cutting OTC Switch Market Exclusivity
“FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is actually seeking such exclusivity,” according to legislative proposals document.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice